Randomizing treatment is not equivalent to validating biomarker-guided intensification in high-risk nasopharyngeal carcinoma. Russi EG. Oral Oncol 2026;177:107970.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Russi EG. Randomizing treatment is not equivalent to validating biomarker-guided intensification in high-risk nasopharyngeal carcinoma. Oral Oncol 2026;177:107970.
PMID: 41955824